| Dat                 | e:April 6 <sup>th</sup> , 2022   |  |  |  |  |
|---------------------|--|--|--|--|--|
|                     | ır Name: Chao  |  |  |  |  |
|                     | Manuscript Title:Study on the clinical features and prognosis of second- and third- generations of COVID-19<br>Manuscript number (if known): |  |  |  |  |
| rela<br>par<br>to t | ated to the content of your ties whose interests may b   | manuscript. "Related" me<br>e affected by the content<br>necessarily indicate a bias | all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so. |  |  |
|                     | e following questions apply<br>nuscript only.  | to the author's relationsl   | hips/activities/interests as they relate to the <u>current</u>   |  |  |
| to t                | •  | ension, you should declar  | e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive a the manuscript.   |  |  |
|                     | tem #1 below, report all su<br>time frame for disclosure i   |  | ted in this manuscript without time limit. For all other items   |  |  |
|                     |  | Name all entities with   | Specifications/Comments  |  |  |
|                     |  | whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)       | (e.g., if payments were made to you or to your institution)  |  |  |
|                     |  | Time frame: Since the initi  | al planning of the work  |  |  |
|                     | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article                       | X None   |  |  |  |
|                     | processing charges, etc.)  No time limit for this item.  |  |  |  |  |
|                     |  |  |  |  |  |
|                     |  | Time frame: pa   | st 36 months   |  |  |
| 2                   | Grants or contracts from any entity (if not indicated in item #1 above).   | XNone  |  |  |  |

Royalties or licenses

Consulting fees

\_X\_\_ None

X\_\_ None

3

| lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      |   |  |
|---|---|--|
| Payment for expert testimony  | _XNone  |  |
| Support for attending meetings and/or travel  | X None  |  |
| Patents planned, issued or pending  | X None  |  |
| Participation on a Data Safety Monitoring Board or Advisory Board                                 | XNone   |  |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone   |  |
| Stock or stock options  | X None  |  |
| Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services         | X None  |  |
| Other financial or non-<br>financial interests  | X None  |  |
|   | onflict of interest in the fol  | lowing box:  |
|   | speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests | speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests  Patents planned  X None  X None  X None  X None  X None |

| Dat                 | te:  | April 6 <sup>th</sup> , 2022                                    |  |  |
|---------------------|--|---|--|--|
| Υοι                 | ur Name:   | Liping  | Chen   |  |
|                     |  | :Study on<br>ber (if known)                                     |  | d prognosis of second- and third- generations of COVID-19_   |
| rela<br>par<br>to t | ated to the co<br>ties whose in<br>transparency  | ontent of your<br>sterests may be<br>and does not i             | manuscript. "Related" re affected by the conter  | e all relationships/activities/interests listed below that are<br>means any relation with for-profit or not-for-profit third<br>nt of the manuscript. Disclosure represents a commitment<br>as. If you are in doubt about whether to list a<br>ndo so. |
|                     | e following qu<br>nuscript only  |   | to the author's relation   | ships/activities/interests as they relate to the <u>current</u>  |
| to t<br>me<br>In i  | the epidemio<br>dication, eve<br>tem #1 below  | logy of hyperton if that medically report all su                | ension, you should decla<br>ation is not mentioned   | be <u>defined broadly</u> . For example, if your manuscript pertain are all relationships with manufacturers of antihypertensive in the manuscript.  Orted in this manuscript without time limit. For all other iten                                   |
|                     |  |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|                     |  |   | •  | itial planning of the work   |
|                     | All support for<br>manuscript (e<br>provision of st<br>medical writin<br>processing cha<br>No time limit | .g., funding,<br>tudy materials,<br>ng, article<br>arges, etc.) | X None   |  |
|                     |  |   | Time frame: p  | past 36 months   |
|                     | Grants or con  |   | X None   |  |

in item #1 above).

Royalties or licenses

Consulting fees

\_X\_\_ None

X\_\_ None

3

| lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      |   |  |
|---|---|--|
| Payment for expert testimony  | _XNone  |  |
| Support for attending meetings and/or travel  | X None  |  |
| Patents planned, issued or pending  | X None  |  |
| Participation on a Data Safety Monitoring Board or Advisory Board                                 | XNone   |  |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone   |  |
| Stock or stock options  | X None  |  |
| Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services         | X None  |  |
| Other financial or non-<br>financial interests  | X None  |  |
|   | onflict of interest in the fol  | lowing box:  |
|   | speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests | speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests  Patents planned  X None  X None  X None  X None  X None |

| Dat                 | e:April 6   | <sup>th</sup> , 2022  |  |                  |  |
|---------------------|---|---|--|------------------|--|
|                     | ır Name:  |   |  |                  |  |
|                     | Manuscript Title:Study on the clinical features and prognosis of second- and third- generations of COVID-19 Manuscript number (if known): |   |  |                  |  |
| rela<br>par<br>to t | ited to the content<br>ties whose interests<br>ransparency and do   | of your manuscript. "Re<br>s may be affected by the                       | lisclose all relationships/activities/interests listed belo<br>ated" means any relation with for-profit or not-for-pr<br>content of the manuscript. Disclosure represents a co<br>te a bias. If you are in doubt about whether to list a<br>nat you do so. | ofit third       |  |
|                     | following question nuscript only.   | s apply to the author's r   | elationships/activities/interests as they relate to the  | <u>current</u>   |  |
| to t                | he epidemiology of  | hypertension, you shou  | should be <u>defined broadly</u> . For example, if your manuld declare all relationships with manufacturers of antitioned in the manuscript.   |                  |  |
|                     | •   | rt all support for the wo<br>losure is the past 36 mo                     | rk reported in this manuscript without time limit. For nths.   | all other items, |  |
|                     |   | Name all entities whom you have relationship or in none (add rows needed) | this (e.g., if payments were made to you or to you dicate institution)   | r                |  |
|                     |   |   | e the initial planning of the work   |                  |  |
| -                   | All support for the promanuscript (e.g., fund provision of study ma medical writing, articl processing charges, e No time limit for this  | esentXNone ding, terials, e tc.)  |  |                  |  |
|                     |   | Time  | rame: past 36 months   |                  |  |
| 2                   | Grants or contracts fr  | omX None  |  |                  |  |

in item #1 above).

Royalties or licenses

Consulting fees

\_X\_\_ None

X\_\_ None

3

| lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      |   |  |
|---|---|--|
| Payment for expert testimony  | _XNone  |  |
| Support for attending meetings and/or travel  | X None  |  |
| Patents planned, issued or pending  | X None  |  |
| Participation on a Data Safety Monitoring Board or Advisory Board                                 | XNone   |  |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone   |  |
| Stock or stock options  | X None  |  |
| Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services         | X None  |  |
| Other financial or non-<br>financial interests  | X None  |  |
|   | onflict of interest in the fol  | lowing box:  |
|   | speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests | speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests  Patents planned  X None  X None  X None  X None  X None |

| Da              | te:April 6 <sup>th</sup> , 2022                            |   |   |
|-----------------|--|---|---|
| Υo              | ur Name: Yaom  | ing Yuan  |   |
| Ma              | nuscript Title:Study on                                    | the clinical features and p   | prognosis of second- and third- generations of COVID-19_  |
| Ma              | nuscript number (if known)                                 | ):  |   |
| rel<br>pa<br>to | ated to the content of your<br>rties whose interests may b | manuscript. "Related" me<br>e affected by the content on<br>necessarily indicate a bias | Il relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. |
|                 | e following questions apply<br>inuscript only.             | to the author's relationsh  | ips/activities/interests as they relate to the <u>current</u>   |
| to<br>me<br>In  | the epidemiology of hypertedication, even if that medic    | ension, you should declare cation is not mentioned in poort for the work reporte        | defined broadly. For example, if your manuscript pertaine all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other iter                                |
|                 |  | Alama all and Maranitals  | Constitution (Constitution)   |
|                 |  | Name all entities with whom you have this   | Specifications/Comments (e.g., if payments were made to you or to your  |
|                 |  | relationship or indicate<br>none (add rows as<br>needed)                                | institution)  |
|                 |  | Time frame: Since the initia  | al planning of the work   |
|                 | All support for the present                                | X None  |   |
|                 | manuscript (e.g., funding,                                 |   |   |
|                 | provision of study materials, medical writing, article     |   |   |
|                 | processing charges, etc.)                                  |   |   |
|                 | No time limit for this item.                               |   |   |
|                 |  |   |   |
|                 |  |   | 4   |
|                 |  |   |   |
|                 |  | Time frame: pas   | t 36 months   |

any entity (if not indicated

\_X\_\_ None

X\_\_ None

in item #1 above).

Consulting fees

Royalties or licenses

3

| lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      |   |  |
|---|---|--|
| Payment for expert testimony  | _XNone  |  |
| Support for attending meetings and/or travel  | X None  |  |
| Patents planned, issued or pending  | X None  |  |
| Participation on a Data Safety Monitoring Board or Advisory Board                                 | XNone   |  |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone   |  |
| Stock or stock options  | X None  |  |
| Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services         | X None  |  |
| Other financial or non-<br>financial interests  | X None  |  |
|   | onflict of interest in the fol  | lowing box:  |
|   | speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests | speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests  Patents planned  X None  X None  X None  X None  X None |

| Dat                 | te:April 6 <sup>th</sup> , 2022                            | !  |   |     |
|---------------------|--|--|---|-----|
|                     |  |  |   |     |
| Ма                  | nuscript Title:Study on                                    | the clinical features and p  | prognosis of second- and third- generations of COVID-19   | _   |
|                     |  |  |   |     |
|                     |  |  |   |     |
| rela<br>par<br>to t | ated to the content of your ties whose interests may b     | manuscript. "Related" me<br>e affected by the content<br>necessarily indicate a bias | Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. |     |
|                     | e following questions apply<br>nuscript only.              | to the author's relationsh   | nips/activities/interests as they relate to the current   |     |
| to t                |  | ension, you should declar  | e <u>defined broadly</u> . For example, if your manuscript pertai<br>e all relationships with manufacturers of antihypertensiv<br>the manuscript.   |     |
|                     | tem #1 below, report all su<br>time frame for disclosure i | • •  | ed in this manuscript without time limit. For all other ite   | ms, |
|                     |  | Name all entities with   | Specifications/Comments   |     |
|                     |  | whom you have this   | (e.g., if payments were made to you or to your  |     |
|                     |  | relationship or indicate   | institution)  |     |
|                     |  | none (add rows as  |   |     |
|                     |  | needed)  |   |     |
|                     |  | Time frame: Since the initia   | al planning of the work   |     |
|                     | All support for the present                                | X None   |   |     |
|                     | manuscript (e.g., funding,                                 |  |   |     |
|                     | provision of study materials, medical writing, article     |  |   |     |
|                     | processing charges, etc.)                                  |  |   |     |
|                     | No time limit for this item.                               |  |   |     |
|                     |  |  |   |     |
|                     |  |  |   |     |
|                     |  | Time frame: pas  | at 36 months  |     |

X\_\_ None

X\_\_ None

\_ None

Grants or contracts from any entity (if not indicated

in item #1 above).

Royalties or licenses

Consulting fees

3

| lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events      |   |  |
|---|---|--|
| Payment for expert testimony  | _XNone  |  |
| Support for attending meetings and/or travel  | X None  |  |
| Patents planned, issued or pending  | X None  |  |
| Participation on a Data Safety Monitoring Board or Advisory Board                                 | XNone   |  |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone   |  |
| Stock or stock options  | X None  |  |
| Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services         | X None  |  |
| Other financial or non-<br>financial interests  | X None  |  |
|   | onflict of interest in the fol  | lowing box:  |
|   | speakers bureaus, manuscript writing or educational events Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests | speakers bureaus, manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non- financial interests  Patents planned  X None  X None  X None  X None  X None |

| Date:  | April 6 <sup>th</sup> , 2022   |  |  |
|--|--|--|--|
| Your Name:_  | Jingh  | ui Li  |  |
| Manuscript Ti  | itle:Study on  | the clinical features and p  | prognosis of second- and third- generations of COVID-19  |
| Manuscript n   | umber (if known)   | :  |  |
|  |  |  |  |
| related to the parties whose to transparen relationship/a The following manuscript of the author's to the epidem medication, e | e content of your e interests may be content of your e interests may be content of your activity/interest, g questions apply nly.  relationships/act niology of hyperteven if that medic | manuscript. "Related" me<br>e affected by the content of<br>necessarily indicate a bias<br>it is preferable that you do<br>to the author's relationsh<br>ivities/interests should be<br>ension, you should declare<br>eation is not mentioned in | ips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive |
|  | •  | s the past 36 months.  | and the manuscripe without time mint. For all other remis  |
|  |  | Name all entities with   | Specifications/Comments  |
|  |  | whom you have this   | (e.g., if payments were made to you or to your   |
|  |  | relationship or indicate   | institution)   |
|  |  | none (add rows as needed)  |  |
|  |  | Time frame: Since the initia   | al planning of the work  |
| All support  | for the present  | X None   | y pariting or the front  |
|  | t (e.g., funding,  |  |  |
| -  | of study materials,  |  |  |
| medical wr   | riting, article  |  |  |
| processing   | charges, etc.)   |  |  |
| No time lin  | nit for this item.   |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  | Time frame: pas  | t 36 months  |
|  | contracts from   | X None   | <u> </u>   |
| in item #1   | (if not indicated  |  |  |
| Royalties o  |  | V None   |  |
| , Royalties 0  | ii iiceiises   | X None   |  |
|  |  |  |  |
| Consulting   | fees   | X None   |  |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _X None                       |              |
|----|--|-------------------------------|--------------|
| 6  | Payment for expert testimony   | _XNone                        |              |
| 7  | Support for attending meetings and/or travel   | X None                        |              |
| 8  | Patents planned, issued or pending   | X None                        |              |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | XNone                         |              |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | XNone                         |              |
| 11 | Stock or stock options   | X None                        |              |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | XNone                         |              |
| 13 | Other financial or non-<br>financial interests   | XNone                         |              |
|    | ease summarize the above co  | onflict of interest in the fo | llowing box: |
|    |  |                               |              |